Cytogenetic and molecular features
| Characteristic . | Arm A: G3139 (n = 190) . | Arm B: control (n = 193) . | Total (n = 383) . | P* . |
|---|---|---|---|---|
| Cytogenetic group | .58† | |||
| Normal karyotype | 76 (40) | 85 (44) | 161 (42) | |
| Complex karyotype | 47 (25) | 38 (20) | 85 (22) | |
| CBF AML | 9 (5) | 5 (3) | 14 (4) | |
| Other balanced rearrangements | 9 (5) | 11 (6) | 20 (5) | |
| Unbalanced abnormalities in noncomplex karyotype | 39 (21) | 36 (19) | 75 (20) | |
| No sample received or rejected cytogenetics | 10 (5) | 18 (9) | 28 (7) | |
| 2017 ELN genetic risk group | .57‡ | |||
| Favorable | 39 (22) | 34 (19) | 73 (21) | |
| Intermediate | 24 (13) | 18 (10) | 42 (12) | |
| Adverse | 37 (37) | 71 (41) | 138 (39) | |
| Unclassifiable | 50 (28) | 52 (30) | 102 (29) | |
| CEBPA double mutation | .95 | |||
| Mutated | 3 (3) | 3 (3) | 6 (3) | |
| WT | 92 (97) | 97 (97) | 189 (97) | |
| NPM1 | .23 | |||
| Mutated | 27 (29) | 34 (38) | 61 (34) | |
| WT | 65 (71) | 56 (62) | 121 (66) | |
| FLT3 ITD | .02 | |||
| Present | 14 (11) | 27 (23) | 41 (17) | |
| Absent | 108 (89) | 92 (77) | 200 (83) | |
| ASXL1 | .02 | |||
| Mutated | 6 (7) | 16 (18) | 22 (12) | |
| WT | 86 (93) | 75 (82) | 160 (88) | |
| RUNX1 | .88 | |||
| Mutated | 14 (15) | 13 (14) | 27 (15) | |
| WT | 78 (85) | 77 (86) | 155 (85) | |
| TP53 | .31 | |||
| Mutated | 15 (16) | 10 (11) | 25 (14) | |
| WT | 77 (84) | 80 (89) | 157 (86) |
| Characteristic . | Arm A: G3139 (n = 190) . | Arm B: control (n = 193) . | Total (n = 383) . | P* . |
|---|---|---|---|---|
| Cytogenetic group | .58† | |||
| Normal karyotype | 76 (40) | 85 (44) | 161 (42) | |
| Complex karyotype | 47 (25) | 38 (20) | 85 (22) | |
| CBF AML | 9 (5) | 5 (3) | 14 (4) | |
| Other balanced rearrangements | 9 (5) | 11 (6) | 20 (5) | |
| Unbalanced abnormalities in noncomplex karyotype | 39 (21) | 36 (19) | 75 (20) | |
| No sample received or rejected cytogenetics | 10 (5) | 18 (9) | 28 (7) | |
| 2017 ELN genetic risk group | .57‡ | |||
| Favorable | 39 (22) | 34 (19) | 73 (21) | |
| Intermediate | 24 (13) | 18 (10) | 42 (12) | |
| Adverse | 37 (37) | 71 (41) | 138 (39) | |
| Unclassifiable | 50 (28) | 52 (30) | 102 (29) | |
| CEBPA double mutation | .95 | |||
| Mutated | 3 (3) | 3 (3) | 6 (3) | |
| WT | 92 (97) | 97 (97) | 189 (97) | |
| NPM1 | .23 | |||
| Mutated | 27 (29) | 34 (38) | 61 (34) | |
| WT | 65 (71) | 56 (62) | 121 (66) | |
| FLT3 ITD | .02 | |||
| Present | 14 (11) | 27 (23) | 41 (17) | |
| Absent | 108 (89) | 92 (77) | 200 (83) | |
| ASXL1 | .02 | |||
| Mutated | 6 (7) | 16 (18) | 22 (12) | |
| WT | 86 (93) | 75 (82) | 160 (88) | |
| RUNX1 | .88 | |||
| Mutated | 14 (15) | 13 (14) | 27 (15) | |
| WT | 78 (85) | 77 (86) | 155 (85) | |
| TP53 | .31 | |||
| Mutated | 15 (16) | 10 (11) | 25 (14) | |
| WT | 77 (84) | 80 (89) | 157 (86) |